Off-target effects of an insect cell-expressed influenza HA-pseudotyped Gag-VLP preparation in limiting postinfluenza Staphylococcus aureus infections.
Animals
Female
Hemagglutinin Glycoproteins, Influenza Virus
/ immunology
Humans
Influenza A Virus, H1N1 Subtype
/ immunology
Influenza Vaccines
/ administration & dosage
Influenza, Human
/ complications
Insecta
Mice
Mice, Inbred BALB C
Staphylococcal Infections
/ prevention & control
Superinfection
/ prevention & control
Vaccination
Vaccines, Virus-Like Particle
/ administration & dosage
Virus Replication
/ immunology
Influenza
Secondary bacterial infection
Staphylococcus aureus
VLP vaccine
Vaccine off-target effects
Journal
Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899
Informations de publication
Date de publication:
22 01 2020
22 01 2020
Historique:
received:
28
06
2019
revised:
21
10
2019
accepted:
26
10
2019
pubmed:
14
11
2019
medline:
11
2
2021
entrez:
14
11
2019
Statut:
ppublish
Résumé
Clinical and historical data underscore the ability of influenza viruses to ally with Staphylococcus aureus and predispose the host for secondary bacterial pneumonia, which is a leading cause of influenza-associated mortality. This is fundamental because no vaccine for S. aureus is available and the number of antibiotic-resistant strains is alarmingly rising. Hence, this leaves influenza vaccination the only strategy to prevent postinfluenza staphylococcal infections. In the present work, we assessed the off-target effects of a Tnms42 insect cell-expressed BEI-treated Gag-VLP preparation expressing the HA of A/Puerto Rico/8/1934 (H1N1) in preventing S. aureus superinfection in mice pre-infected with a homologous or heterologous H1N1 viral challenge strain. Our results demonstrate that matched anti-hemagglutinin immunity elicited by a VLP preparation may suffice to prevent morbidity and mortality caused by lethal secondary bacterial infection. This effect was observed even when employing a single low antigen dose of 50 ng HA per animal. However, induction of anti-hemagglutinin immunity alone was not helpful in inhibiting heterologous viral replication and subsequent bacterial infection. Our results indicate the potential of the VLP vaccine approach in terms of immunogenicity but suggest that anti-HA immunity should not be considered as the sole preventive method for combatting influenza and postinfluenza bacterial infections.
Identifiants
pubmed: 31718898
pii: S0264-410X(19)31472-0
doi: 10.1016/j.vaccine.2019.10.083
pii:
doi:
Substances chimiques
Hemagglutinin Glycoproteins, Influenza Virus
0
Influenza Vaccines
0
Vaccines, Virus-Like Particle
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
859-867Subventions
Organisme : Austrian Science Fund FWF
ID : I 3490
Pays : Austria
Informations de copyright
Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.